Category Archives: Cancer Research

Eric Lefkofsky and Tempus: Leading the Way in Cancer Treatment

Cancer has become a part of American society in recent years with 14.5 million Americans determined to have been battling with the disease as of 2014. 40% of Americans are likely to be diagnosed with cancer at one point in their life, and the National Cancer Institute approximates that 19 million people will suffer from the disease by the year 2024. The future, however, looks more promising owing to the advancements in medical technology brought about by such companies as Tempus. Tempus was co-founded by Eric Lefkofsky and is one of the businesses that are at the forefront of developing data-enabled precision medicine.

Despite the hullabaloo made over the development of electronic health record systems, the healthcare sector has not yet come up to the level of modern technology. It took the diagnosis of breast cancer on Eric Lefkofsky’s wife for him to discover the gap that exists in the medical field as pertains the collection of data and adoption of digital technology in the industry. The massive amounts of patient information collected in the medical centers had not been well corralled to put it into practical use. Tempus was founded to fill this gap in technology adoption and advancement in healthcare sector. The company aims to revolutionize cancer treatment by developing a system which would analyze patients’ data, both clinical and molecular.

Before joining Tempus, Lefkofsky had made a reputation for himself as one of the most influential personalities in the tech field in Chicago through his work at Groupon, which he helped start as well. Lefkofsly left his CEO position in Groupon to take a position as the president of Tempus. He, however, still serves as the chairman of Groupon. Beyond these two companies, the 47-year-old has also help co-found other businesses such as Echo Global Logistics, Mediaocean, Innerworkings, and Uptake. He also helped found Lightbank, the capital venture firm based in Chicago.

Eric Lefkofsly has been involved in charity and philanthropy since 2006 when he formed the Lefkofsky Foundation together with his wife. The foundation has helped in the funding of over 50 organizations since inceptions. In 2013, Lefkofsky joined the Giving pledge together with his wife.

To know more visit @: http://www.lightbank.com/team/eric-lefkofsky

Clay Siegall Appreciates Steps Made In Supporting Cancer Research

 

Research institutes across the world have given attention to the cancer menace and have channeled a lot of energy to research projects that are meant to offer solutions. Many experts like Clay Siegall who took part in this program have also helped to deliver solutions to the problem. Clay Siegall has worked with experts from various regions through his company, Seattle Genetics, which has been conducting research in this field since its launch in 1998. Seattle Genetics has concentrated on offering new technologies and drug pipelines to aid in the treatment of cancer and to achieve high accuracy levels during the process.

Since inception, Seattle Genetics has made several unique drug pipelines and one of their most successful, ADCETRIS, has been adopted widely and supported by other companies through partnerships. Another technology that has placed Seattle Genetics among leading cancer research companies is the ADC Technology, which is a great milestone in the treatment of cancer. Through the technology, one can be treated without the risk of killing other cells in the body and eventually causing harm to the normal state of the individual. As the industry grows further, better ideas are made and Seattle Genetics has promised to continue supporting this pursuit by coming up with reliable treatment solutions.

About Clay Siegall

Clay B. Siegall, the current President and CEO of Seattle Genetics, is an energetic individual, who has for many years supported the fight to deliver better ideas in the fight against cancer. His support in this area has included working with several companies and inviting partnerships to Seattle Genetics to give the research program more strength to unveil superior technologies.

With the partnerships they made with companies like AbbVie and GlaxoSmithKline, Clay Siegall is confident Seattle Genetics will further offer solutions for the treatment of cancer at even cheaper rates that can be accessible to low income earners. His vision is to see a world where people can receive reliable cancer treatment and care without necessarily having to spend a lot of money. So far, Seattle Genetics has successfully produced drug pipelines that were adopted highly and proved to work perfectly to cure cancer.